Indivior PLC Logo

Indivior PLC

Pharmaceutical company developing medicines for substance use and mental disorders.

INDV | IL

Overview

Corporate Details

ISIN(s):
GB00BN4HT335 (+2 more)
LEI:
213800V3NCQTY7IED471
Country:
United Kingdom
Address:
234 BATH ROAD, SL1 4EE SLOUGH

Description

Indivior PLC is a global pharmaceutical company that develops, manufactures, and sells medicines to treat substance use disorders (SUD) and serious mental illnesses. The company's primary focus is on pioneering treatments for opioid use disorder (OUD), with a portfolio centered on buprenorphine-based prescription pharmaceuticals. Through its research and development efforts, Indivior aims to address the complex challenges of addiction and behavioral health by providing innovative, life-transforming therapies for patients worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-24 16:52
Holding(s) in Company
English 23.4 KB
2025-07-24 09:34
Holding(s) in Company
English 25.1 KB
2025-07-23 09:08
Holding(s) in Company
English 25.1 KB
2025-07-21 17:23
Holding(s) in Company
English 25.1 KB
2025-07-21 09:33
Holding(s) in Company
English 25.1 KB
2025-07-18 09:35
Holding(s) in Company
English 25.2 KB
2025-07-17 15:00
Notice of Results
English 10.6 KB
2025-07-01 09:43
Holding(s) in Company
English 56.2 KB
2025-07-01 08:49
Total Voting Rights
English 4.8 KB
2025-06-30 08:00
Indivior Announces Inclusion in US Russell Indexes
English 12.9 KB
2025-06-25 08:00
Indivior Appoints Tony Kingsley to the Board
English 14.0 KB
2025-06-17 17:42
Holding(s) in Company
English 26.7 KB
2025-06-13 09:10
Director/PDMR Shareholding - Correction
English 28.2 KB
2025-06-12 17:24
Director/PDMR Shareholding
English 26.9 KB
2025-06-10 17:12
Holding(s) in Company
English 26.8 KB

Automate Your Workflow. Get a real-time feed of all Indivior PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Indivior PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Indivior PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops IgY-based immune antibodies as alternatives to vaccines and antibiotics.
South Korea
179530
ADC Therapeutics SA Logo
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
A clinical-stage biopharma developing genetically targeted therapies for addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Develops allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
Biopharmaceutical company that develops and manufactures plasma-derived biologics.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
A clinical-stage company developing gene therapies for ocular diseases.
United States of America
ADVM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.